Core Scientific, Inc. – (NASDAQ: CORZ) – Securities Fraud Investigation

Mar 3, 2022 | Shareholder Investigations

Core Scientific Stock – Core Scientific Shareholders With Losses Greater Than $25,000 Encouraged To Contact Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is conducting a securities investigation to determine whether Core Scientific, Inc. (“Core Scientific” or the “Company”) (NASDAQ: CORZ) violated federal securities laws.

IF YOU INVESTED IN CORE SCIENTIFIC STOCK AND SUFFERED LOSSES GREATER THAN $25,000, PLEASE CLICK HERE TO ACCESS KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE TO PROVIDE DETAILS ABOUT YOUR CORZ STOCK LOSSES. 

On March 3, 2022, Seeking Alpha reported (“Crypto miner Core Scientific drops after new short call from Culper Research”) that Core Scientific’s stock price “fell 3.8% after a new short report from Culper Research,” which “alleges that Core Scientific ‘wildly oversold’ both its mining and hosting business. Culper also highlighted that CORZ on Monday disclosed that its board waived a 180-lockup on over 282M shares, which will allow insiders to sell the shares.”

Core Scientific investors with losses greater than $25,000 are also encouraged to contact Kehoe Law Firm, P.C., John Kehoe, Esq., (215) 792-6676, Ext. 801, [email protected], [email protected], for a free, confidential consultation and no-obligation evaluation of potential legal claims.

Verra Mobility Corporation – Securities Fraud Investigation

Mar 1, 2022 | Shareholder Investigations

Securities Fraud Investigation – Verra Mobility Stockholders With Losses Greater Than $25,000 Encouraged To Contact Kehoe Law Firm, P.C. To Discuss Potential Legal Claims.

Kehoe Law Firm, P.C. is conducting a securities investigation to determine whether Verra Mobility Corporation (“Verra Mobility” or the “Company”) (NASDAQ: VRRM) violated federal securities laws.

On February 28, 2022, Verra Mobility announced that it filed a notice of late filing with the SEC, because it will not be able to file its Form 10-K for the year ended December 31, 2021 by the due date of March 1, 2022, and the Company is not expected to do so within the allowable 15-day extension period.

Further, Verra Mobility announced that “[d]uring its year-end 2021 financial statement review process, Verra Mobility . . . determined that revenues from the Company’s recently acquired Australian subsidiary, Redflex Holdings Limited, may not have been recorded in accordance with generally accepted accounting principles. The Company’s Audit Committee is conducting an investigation of the circumstances surrounding these issues to determine, among other things, whether any related adjustment is necessary for the previously issued financial statements for the second and third quarters of fiscal year 2021.”

On this news, Verra Mobility’s stock dropped as much as 7.6% during intraday trading on February 28, 2022, thereby injuring investors.

If you invested in Verra Mobility stock and suffered losses greater than $25,000, please CLICK HERE to provide information about your Verra Mobility stock losses.

Verra Mobility investors with losses greater than $25,000 are also encouraged to contact Kehoe Law Firm, P.C., John Kehoe, Esq., (215) 792-6676, Ext. 801, [email protected], [email protected], for a free, confidential consultation and no-obligation evaluation of potential legal claims.

Evolus, Inc. (NASDAQ: EOLS) – Breach of Fiduciary Duties Investigation

Feb 28, 2022 | Shareholder Investigations

Have You Held Evolus Stock Since May 20, 2019? Evolus Investors May Have Legal Claims Against The Company’s Officers and Directors.

Kehoe Law Firm, P.C. is investigating whether the board of directors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS) breached their fiduciary duties to Evolus and its stockholders.

An amended securities fraud complaint was filed on behalf of investors who purchased Evolus common stock between February 1, 2019 and July 6, 2020, both dates inclusive (the “Class Period”) and who held such shares on March 4, 2019, and/or March 4, 2020 and/or July 6, 2020 and suffered compensable damages thereby (the “Class”).

The amended compliant alleges, among other things, that Evolus made materially false and misleading statements about its injectible botulinum neurotoxin product Jeuveau, which is used to treat wrinkles.

On July 6, 2020, the Initial Final Determination was issued by the United States International Trade Commission (“ITC”) in a case brought by Allergan and Medytox against Evolus, asserting that Evolus stole certain trade secrets to develop Jeuveau™. The ITC Judge determined that the Company misappropriated the botulinum toxin strain as well as the manufacturing processes that led to its development and manufacture.

As a result, the ITC Judge recommended a ten-year long ban on the Company’s ability to import Jeuveau™ into the United States and a ten-year-long cease and desist order preventing Evolus from selling Jeuveau™ in the United States.

On this news, the Company’s share price declined materially, falling 37% over the course of two trading days, to close at $3.35 on July 8, 2020.

Investors Who Have Held Evolus Stock Since May 20, 2019 May Have Legal Claims

If you have held Evolus stock since May 20, 2019, please contact Kehoe Law Firm, P.C., Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, confidential consultation and no-obligation evaluation of potential legal claims.